About the event
Please register through the event page here.
i-net & LSNB Event «Aurealis Pharma: Bacteria-based multi-therapy and successful financing rounds»
Founded in Finland with headquarters in Basel, Aurealis Pharma has developed a bacterial bioreactor, applied locally, that produces and secretes therapeutic human proteins directly into diseased tissue from patients. Their first products are immuno-therapeutics targeting chronic inflammatory wounds and cancer indications. The same technology can be applied to other major unmet indications.
Aurealis Pharma has initially been financed by the founder group and a state owned Finnish VC (Finnvera) and received additional non-dilutive funding from a governmental-owned Finnish agency (Tekes). Recently, the company has relocated their HQ to Basel to advance their lead compound AUP16 towards clinical development. The move did also provide access to the very experienced private investor base found in the region. This has greatly paid out, Aurealis Pharma has been able to collect close to 5.5 million CHF last fall, which came half from local private investors as well as half from non-dilutive funding via Tekes.
This i-net & LSNB event in Basel on May 24th, 2016 (Halle 7, 19:00; door opening 18:45) will have Dirk Weber, Chief Medical Officer of Aurealis Pharma and experienced pharma industry professional, talking about this story and sharing insights and learnings along the way, especially focussing on incorporating the company in Switzerland and successfully completing the last, bilateral financing round.
About Dr. Dirk Weber
Dirk is an MD, PhD with extensive experience in global drug development of anti-cancer drugs.
He did oncology research at Georgetown University, US, at the Institute of General Pathology at University of Kiel and at the Ivonex GmbH in Kiel, Germany. After that he held senior clinical development positions at Merck Serono, Novartis Pharma and Takeda Pharmaceuticals. He has worked in early- and late-stage clinical development programs which included interactions with all major regulatory authorities, dossier filing and lead of submission teams. Dirk also gained extensive experience in the planning and preparations required for several commercial product launches globally.